Mergers & AcquisitionsBy The Online Investor Staff, updated Sun., Jan. 29, 6:00 PM
|This Slide: #40 of 100|
Slide #40. Sun Pharmaceutical Industries Limited — Concert Pharmaceuticals
Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited (Reuters:SUN.BO) (Bloomberg:SUNP.IN) (NSE:SUNPHARMA) (BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) ("Concert") today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of$8.00per share of common stock in cash, or$576 millionin equity value. Concert stockholders will also receive a non-tradeable contingent value right (CVR) entitling holders to receive up to an additional$3.50per share of common stock in cash, payable upon deuruxolitinib achieving certain net sales milestones within specified periods, subject to the terms and conditions contained in a contingent value rights agreement detailing the terms of the CVRs. The transaction was approved by the Boards of Directors of both companies.